AU2003269484A1 - Salt of atorvastatin with metformin - Google Patents
Salt of atorvastatin with metforminInfo
- Publication number
- AU2003269484A1 AU2003269484A1 AU2003269484A AU2003269484A AU2003269484A1 AU 2003269484 A1 AU2003269484 A1 AU 2003269484A1 AU 2003269484 A AU2003269484 A AU 2003269484A AU 2003269484 A AU2003269484 A AU 2003269484A AU 2003269484 A1 AU2003269484 A1 AU 2003269484A1
- Authority
- AU
- Australia
- Prior art keywords
- atorvastatin
- metformin
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
- 229960003105 metformin Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2003/000307 WO2005023766A1 (en) | 2003-09-11 | 2003-09-11 | Salt of atorvastatin with metformin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003269484A1 true AU2003269484A1 (en) | 2005-03-29 |
Family
ID=34259922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003269484A Abandoned AU2003269484A1 (en) | 2003-09-11 | 2003-09-11 | Salt of atorvastatin with metformin |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003269484A1 (en) |
| WO (1) | WO2005023766A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101211227B1 (en) | 2009-08-25 | 2012-12-11 | 한올바이오파마주식회사 | Metformin ascorbic acid salt, preparation thereof, pharmaceutical composition comprising the same and combined formulation comprising the same |
| KR101878252B1 (en) * | 2010-05-26 | 2018-07-13 | 브이티브이 테라퓨틱스 엘엘씨 | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| RS61153B1 (en) | 2011-01-07 | 2020-12-31 | Anji Pharma Us Llc | Chemosensory receptor ligand-based therapies |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| CA2862533C (en) | 2012-01-06 | 2021-05-04 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| EP2800562A2 (en) | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| IN2014DN09554A (en) | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| CA2878625A1 (en) * | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP4487909A3 (en) | 2018-06-12 | 2025-03-19 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| US20030171407A1 (en) * | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
-
2003
- 2003-09-11 AU AU2003269484A patent/AU2003269484A1/en not_active Abandoned
- 2003-09-11 WO PCT/IN2003/000307 patent/WO2005023766A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005023766A1 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1632477T (en) | Benzamide derivative or salt thereof | |
| EP1683784A4 (en) | Diimonium salt compound and use thereof | |
| AU2003268687A1 (en) | Novel salt of 2-acylaminothiazole derivative | |
| AU2003269484A1 (en) | Salt of atorvastatin with metformin | |
| AU2003297594A1 (en) | Crystalline form f of atorvastatin hemi-calcium salt | |
| AU2003302645A1 (en) | Synthesis of pyrrolidine compound and salt thereof | |
| AU2003269485A1 (en) | Salt of atorvastatin with ranitidine | |
| AU2003902208A0 (en) | Inhibitor of cox | |
| AU2003289836A1 (en) | Flat gasket | |
| AU2003238034A1 (en) | Novel use of imidazotriazinones | |
| AU2003903205A0 (en) | New compound | |
| AU2003903629A0 (en) | New compound | |
| AU2003255130A1 (en) | Inclusion compound of nateglinide | |
| AU2003900207A0 (en) | New compounds | |
| AU2003905200A0 (en) | Fish hooka | |
| AU2003905562A0 (en) | Automastic Adhesive Cartridge Cylinder | |
| AU2003902622A0 (en) | Amide compounds | |
| AU2003246752A1 (en) | Use of densin-like compounds | |
| HK1073063A (en) | Novel formate salt of o-desmethyl-venlafaxine | |
| HK1095309A (en) | Chemiluminescent vessel | |
| AU2003201887A1 (en) | 2-acylaminothiazole derivative or salt thereof | |
| AU2003904500A0 (en) | Novel compounds II | |
| GB0206255D0 (en) | Novel salt forms | |
| HK1086276A (en) | Novel compounds | |
| AU2003904509A0 (en) | Novel Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |